Benitec Biopharma (BNTC) said Tuesday it has priced an offering of about 1.4 million shares or pre-funded warrants and a concurrent registered direct offering of 900,000 shares of its common stock with long-term investor Suvretta Capital at $13.00 per share and $12.9999 per warrant.
The pre-funded warrants will be immediately exercisable, the company said.
The offerings are expected to close on Wednesday, the company said.
Gross proceeds to Benitec from the offerings are expected to be approximately $30 million, the company said.
The company said it intends to use the net proceeds, together with existing cash on hand, to finance continued development of its drug candidates and other general corporate purposes.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.